Results 111 to 120 of about 33,657 (222)

Vaccination and transfusion safety at the time of expanding use of live attenuated vaccines

Vox Sanguinis, EarlyView.
Pierre Tiberghien, Pierre Gallian, Virginie de La Taille, Caroline Bacquet, Syria Laperche   +4 more
wiley   +1 more source

Assessing Risk Thresholds in Controlled Human Infection Models (CHIM)

Bioethics, Volume 40, Issue 5, Page 519-529, June 2026.
ABSTRACT Controlled Human Infection Models (CHIMs) are a type of clinical trial involving deliberately exposing human volunteers to an infectious agent. Compared to studies of natural infection, CHIMs offers distinctive benefits, from the ability to study presymptomatic infection to a direct assessment of the efficacy of vaccines and therapeutics in a ...
Alexa Nord‐Bronzyk, Barnaby Young, Jerry Menikoff, Julian Savulescu, G. Owen Schaefer   +4 more
wiley   +1 more source

Under-recognition and reporting of dengue in Cambodia: a capture–recapture analysis of the National Dengue [PDF]

, 2011
Robust disease burden estimates are important for decision-making concerning introduction of new vaccines. Dengue is a major public health problem in the tropics but robust disease burden estimates are lacking.
Margolis, H. S., S. Goyet, Ngan, C., G. W. Letson, O. Wichmann, Wichmann, O., Vong, S., R. Huy, Surveillance System, P. Buchy, Goyet, S., Ly, S., C. Ngan, S. Ly, Letson, G. W., Wichmann, Ole, S. Vong, Huy, R., V. Duong, Duong, V., H. S. Margolis, Buchy, P.   +21 more
core   +1 more source

A novel single-dose dengue subunit vaccine induces memory immune responses.

, 2011
To protect against dengue viral infection, a novel lipidated dengue subunit vaccine was rationally designed to contain the consensus amino acid sequences derived from four serotypes of dengue viruses.
Chen-Yi Chiang, Pele Chong, Jy-Ping Tsai, Yi-Shiuan Li, Shih-Jen Liu, Hsin-Wei Chen, Mei-Yu Chen, Chih-Hsiang Leng, Hsueh-Hung Liu, Chiang, CY;Liu, SJ;Tsai, JP;Li, YS;Chen, MY;Liu, HH;Chong, P;Leng, CH;Chen, HW   +9 more
core   +1 more source

Designing of a multiepitope-based chimeric vaccine against dengue virus serotype 3 (DENV-3) through next generation reverse vaccinology approaches

Informatics in Medicine Unlocked
The dengue virus (DENV) causes dengue infection and has become a significant global public health concern. The successful application of immunotherapies in treating dengue infection has paved the way for developing various treatment strategies.
Md Habib Ullah Masum, Jannatul Ferdous, Syed Lokman, Amam Zonaed Siddiki   +3 more
doaj   +1 more source

Dengue Vector Dynamics in Pakistan [PDF]

, 2012
During the last few year dengue has become an emerging vector borne disease in Pakistan. Aedes aegypti once considered eradicated from almost whole of Pakistan was again collected from 13 different cities.
Rasheed, Syed Basit
core  

Dengue Fever: Causes, Complications, and Vaccine Strategies

Journal of Immunology Research, 2016
Dengue is a highly endemic infectious disease of the tropical countries and is rapidly becoming a global burden. It is caused by any of the 4 serotypes of dengue virus and is transmitted within humans through female Aedes mosquitoes.
Niyati Khetarpal, Ira Khanna
doaj   +1 more source

Severe dengue hemorrhagic fever after TAK-003 dengue vaccination: A case report of a potential vaccine-associated adverse reaction

International Journal of Infectious Diseases
We report a severe dengue case that developed symptoms 5 days post-TAK-003 dengue vaccine administration. Whole-genome sequencing confirmed co-detection of all four dengue serotypes with high similarity to vaccine strains, especially DENV-2. This finding
Pinyo Rattanaumpawan, Navin Horthongkham, Kamol Suwannakarn, Artittaya Athipanyasilp, Ubonvan Jongwutiwes   +4 more
doaj   +1 more source

An Updated Comprehensive Review of the Dengue Vaccine: Development, Mechanism, Efficacy, and Safety

Journal of Bio-X Research
Dengue virus (DENV) is spread through bites from mosquitos of the Aedes genus. DENV activates antibodies against 4 dengue serotypes, which are identified by the plaque reduction neutralization test of 50%, and the dengue antivirals use nonstructural ...
Manoj Ramesh Kumbhare, Siddhi M. Chandak, Aishwarya Balasaheb Dukare, Vaibhavi Vijay Kshatriya, Sakshi S. Velhal   +4 more
doaj   +1 more source

Next-Generation Dengue Vaccines: Novel Strategies Currently Under Development

Viruses, 2011
Dengue has become the most important arboviral infection worldwide with more than 30 million cases of dengue fever estimated to occur each year. The need for a dengue vaccine is great and several live attenuated dengue candidate vaccines are proceeding ...
Anna P. Durbin, Stephen S. Whitehead
doaj   +1 more source